Overcoming breast cancer heterogeneity and resistance using a novel therapeutic approach targeting the metastasis suppressor NDRG1.

使用针对转移抑制因子 NDRG1 的新型治疗方法克服乳腺癌异质性和耐药性。

• 批准号: nhmrc : 1140447
• 负责人: Dr Zaklina Kovacevic
• 金额: $ 29.14万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Career Development Fellowships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/overcoming-breast-cancer-suppressor-ndrg1/1319242
• 关键词: Overcoming; breast; cancer; heterogeneity; resistance

Breast cancer (BrCa) is the leading cause of cancer death in women and current treatments suffer from development of resistance, leading to metastatic progression. I will assess a novel treatment strategy for BrCa, targeting a gene that is able to inhibit multiple key drivers of BrCa, using a novel potent and selective anti-cancer agent. This approach has the potential to overcome resistance to current therapies and alleviate the onset of metastasis, to improve prognosis for BrCa patients.

乳腺癌(BRCA)是女性癌症死亡的主要原因，目前的治疗方法存在耐药性，导致转移进展。我将评估BRCA的一种新的治疗策略，使用一种新的有效和选择性的抗癌药物，瞄准一种能够抑制BRCA多个关键驱动因素的基因。这种方法有可能克服对现有治疗的抵抗力，减轻转移的发生，改善BRCA患者的预后。